Leuprolide

CAMCEVI, ELIGARD, Fensolvi, LUTRATE DEPOT, Lupron Depot, Lupron Depot-PED, Vabrinty

Gonadotropin Releasing Hormone Receptor Agonist

NADAC/unit $220.1220

No Shortage Tier 1: 187.8% PA Req: 935.9% 8 Manufacturers 8 ANDAs

VABRINTY is indicated for the treatment of advanced prostate cancer.

vs. brand CAMCEVI: Generic saves up to -2101% per unit

Covered Lives

Market Intelligence

2023-10-04 Class III Recall: Tolmar, Inc.

Generic Manufacturers

ABBVIE ENDOCRINE INCACCORD BIOPHARMA INCAMNEAL EU LTDEUGIA PHARMA SPECIALITIES LTDINVAGEN PHARMACEUTICALS INCMEITHEAL PHARMACEUTICALS INCSANDOZ INCSOMERSET THERAPEUTICS LLCSUN PHARMACEUTICAL INDUSTRIES LTDTOLMAR INCTOLMAR INTERNATIONAL LTDUBI PHARMA INCZYDUS PHARMACEUTICALS USA INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Leuprolide drfinder.aiFind doctors who prescribe Leuprolide rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Leuprolide

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.